{"title":"沙特阿拉伯 2 型糖尿病患者低密度脂蛋白胆固醇目标值的实现情况","authors":"Laura Alolayan, Ghadah Al Rajeh","doi":"10.21474/ijar01/18349","DOIUrl":null,"url":null,"abstract":"Background: Diabetes mellitus (DM) is one of the most common diseases in the world and Cardiovascular diseases (CVD) is among the most common preventable complication of DM. Low-density lipoprotein cholesterol (LDL-C) is known to be a major risk factor for developing CVD. Many guidelines have suggested that controlling LDL-C can contribute to lower the mortality among CVD patients. Aim: To assess Achievement of Target LDL-C in type 2 DM patients in Saudi Arabia, and the prevalence of Lipid lowering agents use among these patients. Data sources: PubMed, Cochrane Library, Science Direct, Embase, and Google Scholar. Methods: Non interventional retrospective cross sectional study. Results: The study included 100 patients, age range was between 25 – 82 years old with a Mean age of 51,60. 51% of the participants were males, while 49% were females. 23% of the patients had optimal LDL cholesterol levels below 1,8 mmol/L, while 77% of had suboptimal levels above 1,8 mmol/L. SpearmanÂ’s rank correlation was computed to assess the relationship between LDL and BMI. There was a positive correlation between the two variables, r = 0,071, p = 0,484. The correlation was not significant at the 0,05 level of significance. SpearmanÂ’s rank correlation was computed to assess the relationship between LDL and A1C. There was a positive correlation between the two variables, r = 0,051, p = 0,612. The correlation was not significant at the 0,05 level of significance. The most used medication for lowering cholesterol was atorvastatin, which was taken by 64% of the patients, followed by rosuvastatin, 23% of the patients, 4% of the patients used simvastatin, and 9% of the patients did not receive any treatment and was not offered to them in their follow up visit. 54% of patients who were receiving Lipid lowering therapy did not had dose adjustments during their regular follow up. Conclusion: It is extremely important to achive targeted LDL-C in diabetic patients. Physicians should always aim to reach the targeted level by following the latest guidelines and encouraging patients compliance to medications and lifestyle modifications hence preventing the complications.","PeriodicalId":13781,"journal":{"name":"International Journal of Advanced Research","volume":"21 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ACHIEVEMENT OF TARGET LDL-C IN TYPE 2 DM PATIENTS IN SAUDI ARABIA\",\"authors\":\"Laura Alolayan, Ghadah Al Rajeh\",\"doi\":\"10.21474/ijar01/18349\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Diabetes mellitus (DM) is one of the most common diseases in the world and Cardiovascular diseases (CVD) is among the most common preventable complication of DM. Low-density lipoprotein cholesterol (LDL-C) is known to be a major risk factor for developing CVD. Many guidelines have suggested that controlling LDL-C can contribute to lower the mortality among CVD patients. Aim: To assess Achievement of Target LDL-C in type 2 DM patients in Saudi Arabia, and the prevalence of Lipid lowering agents use among these patients. Data sources: PubMed, Cochrane Library, Science Direct, Embase, and Google Scholar. Methods: Non interventional retrospective cross sectional study. Results: The study included 100 patients, age range was between 25 – 82 years old with a Mean age of 51,60. 51% of the participants were males, while 49% were females. 23% of the patients had optimal LDL cholesterol levels below 1,8 mmol/L, while 77% of had suboptimal levels above 1,8 mmol/L. SpearmanÂ’s rank correlation was computed to assess the relationship between LDL and BMI. There was a positive correlation between the two variables, r = 0,071, p = 0,484. The correlation was not significant at the 0,05 level of significance. SpearmanÂ’s rank correlation was computed to assess the relationship between LDL and A1C. There was a positive correlation between the two variables, r = 0,051, p = 0,612. The correlation was not significant at the 0,05 level of significance. The most used medication for lowering cholesterol was atorvastatin, which was taken by 64% of the patients, followed by rosuvastatin, 23% of the patients, 4% of the patients used simvastatin, and 9% of the patients did not receive any treatment and was not offered to them in their follow up visit. 54% of patients who were receiving Lipid lowering therapy did not had dose adjustments during their regular follow up. Conclusion: It is extremely important to achive targeted LDL-C in diabetic patients. Physicians should always aim to reach the targeted level by following the latest guidelines and encouraging patients compliance to medications and lifestyle modifications hence preventing the complications.\",\"PeriodicalId\":13781,\"journal\":{\"name\":\"International Journal of Advanced Research\",\"volume\":\"21 8\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Advanced Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21474/ijar01/18349\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Advanced Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21474/ijar01/18349","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
ACHIEVEMENT OF TARGET LDL-C IN TYPE 2 DM PATIENTS IN SAUDI ARABIA
Background: Diabetes mellitus (DM) is one of the most common diseases in the world and Cardiovascular diseases (CVD) is among the most common preventable complication of DM. Low-density lipoprotein cholesterol (LDL-C) is known to be a major risk factor for developing CVD. Many guidelines have suggested that controlling LDL-C can contribute to lower the mortality among CVD patients. Aim: To assess Achievement of Target LDL-C in type 2 DM patients in Saudi Arabia, and the prevalence of Lipid lowering agents use among these patients. Data sources: PubMed, Cochrane Library, Science Direct, Embase, and Google Scholar. Methods: Non interventional retrospective cross sectional study. Results: The study included 100 patients, age range was between 25 – 82 years old with a Mean age of 51,60. 51% of the participants were males, while 49% were females. 23% of the patients had optimal LDL cholesterol levels below 1,8 mmol/L, while 77% of had suboptimal levels above 1,8 mmol/L. Spearman’s rank correlation was computed to assess the relationship between LDL and BMI. There was a positive correlation between the two variables, r = 0,071, p = 0,484. The correlation was not significant at the 0,05 level of significance. Spearman’s rank correlation was computed to assess the relationship between LDL and A1C. There was a positive correlation between the two variables, r = 0,051, p = 0,612. The correlation was not significant at the 0,05 level of significance. The most used medication for lowering cholesterol was atorvastatin, which was taken by 64% of the patients, followed by rosuvastatin, 23% of the patients, 4% of the patients used simvastatin, and 9% of the patients did not receive any treatment and was not offered to them in their follow up visit. 54% of patients who were receiving Lipid lowering therapy did not had dose adjustments during their regular follow up. Conclusion: It is extremely important to achive targeted LDL-C in diabetic patients. Physicians should always aim to reach the targeted level by following the latest guidelines and encouraging patients compliance to medications and lifestyle modifications hence preventing the complications.